Europe Protein Therapeutics Market

Europe Protein Therapeutics Market Size (2024 to 2029)

The size of the Europe Protein Therapeutics market was worth USD 45.17 billion in 2024. It is further expected to grow at a CAGR of 6.3% and value USD 61.31 billion by 2029. It captures 25% of the global market.

Protein therapeutics are most often employed in the treatment of chronic ailments like cancer etc. This market has enormous potential in the coming years. Protein therapy refers to drugs made from proteins that are artificially synthesized. These are powerful, fast-acting drugs that deliver small protein molecules to the body in a specific amount. 

Protein therapeutics are related to drugs made from proteins that are artificially synthesized. These drugs help in the treatment of various chronic medical conditions, such as cancer, diabetes, inflammatory diseases, hormonal disorders, etc. These proteins can be in the form of monoclonal antibodies, which are widely studied and used for the treatment of various viral and bacterial diseases. Protein therapeutics are heavily focused by pharmaceutical companies for drug discovery and development. The development of new recombinant proteins, antibody-based drugs, and plasma-derived proteins act like other cellular growth-inducing factors. Additionally, the extensive research and development in the European protein therapeutics market, growing awareness of people, well-developed healthcare infrastructure, the increasing prevalence of chronic diseases, and all these above-mentioned factors are expected to drive the European protein therapeutics market.

Improving the standard of living in the United Kingdom and some European countries is greatly expanding the therapeutic market for proteins. These synthetically engineered proteins are usually ingested in the form of pills, injections, and inhalation form. The growing awareness about the benefits of artificially engineered proteins is contributing to the growth of the European protein therapeutics market. These protein therapeutics are also showing tremendous demand for the treatment for neurodegenerative disorders, genetic and autoimmune disorders, such as dysfibrinogenemia, Marfan syndrome, and afibrinogenesis, etc.  

However, strict government regulations and reimbursement policies in some developed countries are expected to restrain the growth rate of the Europe protein therapeutics market. In addition, the lack of awareness, the high price associated with the recombinant products, and the lack of essential funds for research and development are other key constraints for the studied market in the upcoming years.

This research report on the European protein therapeutics market has been segmented and sub-segmented into the following categories:

By Product:

• Monoclonal Antibodies

• Insulin

• Fusion Protein

• Erythropoietin

• Interferon

• Human Growth Hormone

• Follicle Stimulating Hormone

By Application:

• Metabolic Disorders

• Immunologic Disorders

• Hematological Disorders

• Cancer

• Hormonal Disorders

• Genetic Disorders

• Others

By Therapeutic Modalities: 

• Protein Diagnostics

• Protein Vaccines

• Protein Therapeutics with Special Targeting Activity

• Protein Therapeutics with Enzymatic Or Regulatory Activity

By Country: 

• UK

• France

• Spain

• Germany

• Italy

• Russia

• Sweden

• Denmark

• Switzerland

• Netherlands

• Turkey

• Czech Republic

• Rest of Europe

Based on region, The European protein therapeutics market is accounted for a significant share in the global market in 2020. In the growth of the regional market in Europe, the United Kingdom has maintained a dominant market share, owing to the presence of a large geriatric population and the high prevalence of other chronic diseases. Additionally, the adoption of protein therapeutics in government initiatives and reimbursement programs and the untapped potential of developing sectors should offer lucrative opportunities to market players. The availability of advanced healthcare infrastructure, technological advancements in healthcare sectors will help in rising the regional revenues. In 2020, total health spending peaked at 9.8% of the country's gross domestic product, also due to the country's response to healthcare emergencies such as the covid-29 pandemic.

The Italian healthcare share in the country’s GDP was slightly above the European average, which was 8.9% in 2018. In 2020, Italy showed the highest regional growth for protein therapeutics with high demand for recombinant protein drugs. The market is also expected to show increased healthcare expenditure, increased cases of chronic inflammatory diseases, thereby expanding the European protein therapeutics market during the projected period. The growth of the regional market is also driven by the growing base for international key market players.

The Europe protein therapeutics market in countries namely Sweden, Spain, France, and the Netherlands will also grow at a healthy growth rate, mainly attributed to the development of market enterprises in the untapped regions, the increase in R&D in the healthcare sector, the growing emphasis for vaccinations to stop various diseases and a huge target population is some of the influences influencing the growth of the regional markets in these areas.

On the other hand, it is predicted that Ukraine will witness to be a small part of the European protein therapeutics market growth during the forecast period. This sluggish growth rate will be due to the poor economy and healthcare standards.

Key players operating in the Europe Protein Therapeutics Market profiled in this report are Baxter International Inc., Eli Lilly, and Company, Abbott Laboratories, Amgen Inc., F. Hoffmann-La Roche Ltd. Other players in the market are Novo Nordisk A/S, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., and Sanofi.